FCM
Farallon Capital Management’s Boston Scientific BSX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $428M | Buy |
3,981,057
+218,300
| +6% | +$23.4M | 1.84% | 19 |
|
|
2025
Q1 | $380M | Sell |
3,762,757
-1,260,200
| -25% | -$127M | 1.88% | 19 |
|
|
2024
Q4 | $449M | Sell |
5,022,957
-402,700
| -7% | -$36M | 2.01% | 16 |
|
|
2024
Q3 | $455M | Buy |
5,425,657
+1,316,500
| +32% | +$110M | 2.01% | 14 |
|
|
2024
Q2 | $316M | Sell |
4,109,157
-487,500
| -11% | -$37.5M | 1.36% | 24 |
|
|
2024
Q1 | $315M | Sell |
4,596,657
-1,223,600
| -21% | -$83.8M | 1.34% | 20 |
|
|
2023
Q4 | $336M | Buy |
5,820,257
+781,000
| +15% | +$45.1M | 1.54% | 17 |
|
|
2023
Q3 | $266M | Sell |
5,039,257
-6,000
| -0.1% | -$317K | 1.24% | 26 |
|
|
2023
Q2 | $273M | Sell |
5,045,257
-2,660,000
| -35% | -$144M | 1.37% | 27 |
|
|
2023
Q1 | $385M | Sell |
7,705,257
-1,555,000
| -17% | -$77.8M | 2.11% | 15 |
|
|
2022
Q4 | $428M | Sell |
9,260,257
-2,891,000
| -24% | -$134M | 2.53% | 6 |
|
|
2022
Q3 | $471M | Sell |
12,151,257
-2,896,000
| -19% | -$112M | 2.58% | 5 |
|
|
2022
Q2 | $561M | Sell |
15,047,257
-693,000
| -4% | -$25.8M | 3.04% | 4 |
|
|
2022
Q1 | $697M | Sell |
15,740,257
-1,074,324
| -6% | -$47.6M | 3.36% | 3 |
|
|
2021
Q4 | $714M | Buy |
16,814,581
+2,812,000
| +20% | +$119M | 3.57% | 2 |
|
|
2021
Q3 | $608M | Buy |
14,002,581
+1,285,962
| +10% | +$55.8M | 2.84% | 2 |
|
|
2021
Q2 | $544M | Sell |
12,716,619
-106,250
| -0.8% | -$4.54M | 2.22% | 7 |
|
|
2021
Q1 | $496M | Sell |
12,822,869
-415,450
| -3% | -$16.1M | 2.46% | 8 |
|
|
2020
Q4 | $476M | Buy |
13,238,319
+4,962,400
| +60% | +$178M | 2.86% | 7 |
|
|
2020
Q3 | $316M | Buy |
+8,275,919
| New | +$316M | 2.19% | 16 |
|